Understanding real-world outcomes in patients with NSCLC who progress on 1st-/2nd-generation EGFR TKIs.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20589
Abstract: e20589Background: Epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors (TKIs) are recommended for patients (pts) with EGFR mutation (EGFRm) positive non-small cell lung cancer (NSCLC).... read more here.
Keywords: real world; outcomes patients; world outcomes; understanding real ... See more keywords